NPCE - NeuroPace, Inc. Stock Price, Fair Value and News

$16.66+0.64 (+4.00%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

NPCE Price Action

Last 7 days

1.0%

Last 30 days

77.2%

Last 90 days

73.4%

Trailing 12 Months

39.7%

NPCE RSI Chart

NPCE Valuation

Market Cap

554.9M

Price/Earnings (Trailing)

-23.13

Price/Sales (Trailing)

5.85

Price/Free Cashflow

-33.68

NPCE Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

NPCE Fundamentals

NPCE Revenue

Revenue (TTM)

94.9M

Rev. Growth (Yr)

29.89%

Rev. Growth (Qtr)

16.3%

NPCE Earnings

Earnings (TTM)

-24.0M

Earnings Growth (Yr)

35.88%

Earnings Growth (Qtr)

59.59%

NPCE Profitability

Return on Equity

-129.53%

Return on Assets

-22.36%

Free Cashflow Yield

-2.97%

NPCE Investor Care

Shares Dilution (1Y)

11.59%

Diluted EPS (TTM)

-0.74

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	84.3M	88.6M	94.9M	0
2024	69.1M	71.8M	76.5M	79.9M
2023	48.6M	54.9M	60.2M	65.4M
2022	45.3M	42.9M	43.7M	45.5M
2021	42.4M	47.4M	44.9M	45.2M
2020	0	0	0	41.1M

Get all data in R, Python etc through our Historical Stock Data APIs

About NeuroPace, Inc.

NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. The company's RNS system also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip leads and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

CEO	Mr. Joel D. Becker
WEBSITE	neuropace.com
SECTOR	Healthcare
INDUSTRY	Medical Devices
EMPLOYEES	169

NeuroPace, Inc. Frequently Asked Questions

What is the ticker symbol for NeuroPace, Inc.? What does NPCE stand for in stocks?

NPCE is the stock ticker symbol of NeuroPace, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of NeuroPace, Inc. (NPCE)?

As of Wed Dec 03 2025, market cap of NeuroPace, Inc. is 554.91 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NPCE stock?

You can check NPCE's fair value in chart for subscribers.

Is NeuroPace, Inc. a good stock to buy?

The fair value guage provides a quick view whether NPCE is over valued or under valued. Whether NeuroPace, Inc. is cheap or expensive depends on the assumptions which impact NeuroPace, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NPCE.

What is NeuroPace, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, NPCE's PE ratio (Price to Earnings) is -23.13 and Price to Sales (PS) ratio is 5.85. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NPCE PE ratio will change depending on the future growth rate expectations of investors.